No Detail Found!

A randomized trial of Letrozole in postmenopausal women after five years of Tamoxifen therapy for early-stage Breast Cancer.

Author(s)
Paul E. Goss Division of Hematology-Oncology, Princess Margaret Hospital, Toronto, ON, Canada
James N. Ingle FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02115
Silvana Martino FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02116
Nicholas J. Robert FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02117
Hyman B. Muss FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02118
Martine J. Piccart FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02119
Monica Castiglione FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02120
Dong Sheng Tu FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02121
Lois E. Shepherd FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02122
Kathleen I. Pritchard FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02123
Robert B. Livingston FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02124
Nancy E. Davidson FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02125
Larry Norton FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02126
Edith A. Perez FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02127
Jeffrey S. Abram FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02128
Patrick Therasse FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02129
Michael J. Palmer FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02130
Joseph L. Pater FRCP (UK), Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Suite 640, Boston, MA 02131
Abstract
Background: In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy - but not tamoxifen therapy of longer duration prolongs disease free and overall survival. The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy. Methods: We conducted a double-blind, placebo controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy. The primary end point was disease free survival. Results: A total of 5187 women were enrolled (median follow-up, 2.4 years). At the first interim analysis, there were 207 local or metastatic recurrences of breast cancer or new primary cancers in the contralateral breast - 75 in the letrozole group and 132 in the placebo group - with estimated, four-year disease-free survival rates of 93 percent and 87 percent, respectively, in the two groups (P
Publication Details
Page(s) 24-30
DOI DOI not available
Published Journal: Medical Channel: Journal of Modern Dental and Medical Sciences, Volume: 10, Issue: 3, Year: 2004

Request the full text from PASTIC

0

Citations

0

Downloads

54

Views